Investigational Drug Details
| Drug ID: | D197 |
| Drug Name: | Lactobacillus spp |
| Synonyms: | Lactobacillus reuteri V3401 |
| Type: | Supplement |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial completed (NCT02972567: This is the first time that L. reuteri V3401 will be evaluated in patients with IRS. Therefore, this study will provide valuable scientific information about the effects of this strain in metabolic syndrome patients.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0992 | NCT02972567 | Not applicable | Completed | No Results Available | May 2016 | July 13, 2020 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A14502 | 29379536 | Arch Med Sci | Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? | Details |
| A18879 | 26890069 | Mol Nutr Food Res | Fuzhuan tea consumption imparts hepatoprotective effects and alters intestinal microbiota in high saturated fat diet-fed rats. | Details |
| A24062 | 24933975 | Eksp Klin Gastroenterol | [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome]. | Details |